This document sets out in detail the new framework for appraising, evaluating and funding all cancer drugs, including the operation of the new Cancer Drugs Fund. It is the product of partnership working between NHS England, the National Institute for Health and Care Excellence, Public Health England, and the Department of Health and has been informed by further engagement with patient groups and industry.